JP2016535741A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535741A5 JP2016535741A5 JP2016526141A JP2016526141A JP2016535741A5 JP 2016535741 A5 JP2016535741 A5 JP 2016535741A5 JP 2016526141 A JP2016526141 A JP 2016526141A JP 2016526141 A JP2016526141 A JP 2016526141A JP 2016535741 A5 JP2016535741 A5 JP 2016535741A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- amino acids
- seq
- endoglin polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 102100037241 Endoglin Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 108010036395 Endoglin Proteins 0.000 claims 19
- 150000001413 amino acids Chemical class 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 238000010494 dissociation reaction Methods 0.000 claims 8
- 230000005593 dissociations Effects 0.000 claims 8
- 208000019425 cirrhosis of liver Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims 2
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000003176 fibrotic effect Effects 0.000 claims 2
- 102000052974 human BMP10 Human genes 0.000 claims 2
- 102000046041 human GDF2 Human genes 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 101001052035 Homo sapiens Fibroblast growth factor 2 Proteins 0.000 claims 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 claims 1
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 claims 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000000013 bile duct Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 102000058223 human VEGFA Human genes 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 230000004807 localization Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361896002P | 2013-10-25 | 2013-10-25 | |
| US61/896,002 | 2013-10-25 | ||
| PCT/US2014/062147 WO2015061666A1 (en) | 2013-10-25 | 2014-10-24 | Endoglin peptides to treat fibrotic diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019115063A Division JP6994481B2 (ja) | 2013-10-25 | 2019-06-21 | 線維性疾患を処置するためのエンドグリンポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016535741A JP2016535741A (ja) | 2016-11-17 |
| JP2016535741A5 true JP2016535741A5 (enExample) | 2017-11-30 |
| JP6546587B2 JP6546587B2 (ja) | 2019-07-17 |
Family
ID=51894230
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016526141A Expired - Fee Related JP6546587B2 (ja) | 2013-10-25 | 2014-10-24 | 線維性疾患を処置するためのエンドグリンポリペプチド |
| JP2019115063A Expired - Fee Related JP6994481B2 (ja) | 2013-10-25 | 2019-06-21 | 線維性疾患を処置するためのエンドグリンポリペプチド |
| JP2021201819A Pending JP2022058352A (ja) | 2013-10-25 | 2021-12-13 | 線維性疾患を処置するためのエンドグリンポリペプチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019115063A Expired - Fee Related JP6994481B2 (ja) | 2013-10-25 | 2019-06-21 | 線維性疾患を処置するためのエンドグリンポリペプチド |
| JP2021201819A Pending JP2022058352A (ja) | 2013-10-25 | 2021-12-13 | 線維性疾患を処置するためのエンドグリンポリペプチド |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20150202260A1 (enExample) |
| EP (2) | EP3060235B1 (enExample) |
| JP (3) | JP6546587B2 (enExample) |
| KR (2) | KR102354787B1 (enExample) |
| CN (1) | CN105899225A (enExample) |
| AU (2) | AU2014339898B2 (enExample) |
| CA (1) | CA2928708A1 (enExample) |
| EA (2) | EA035481B1 (enExample) |
| WO (1) | WO2015061666A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8642031B2 (en) | 2006-11-02 | 2014-02-04 | Acceleron Pharma, Inc. | Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof |
| AU2012245439B2 (en) | 2011-04-20 | 2017-04-06 | Acceleron Pharma, Inc. | Endoglin polypeptides and uses thereof |
| EA035481B1 (ru) | 2013-10-25 | 2020-06-23 | Акселерон Фарма, Инк. | Эндоглиновые пептиды для лечения фиброзных заболеваний |
| AU2016273028B2 (en) * | 2015-06-05 | 2019-02-14 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor |
| JP7159148B2 (ja) * | 2016-07-07 | 2022-10-24 | アクセルロン ファーマ インコーポレイテッド | Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 |
| CN106994181A (zh) * | 2017-03-10 | 2017-08-01 | 上海交通大学医学院附属第九人民医院 | Bmp9在制备延缓肝纤维化药物中的应用 |
| WO2020022438A1 (ja) * | 2018-07-26 | 2020-01-30 | 参天製薬株式会社 | 網膜線維化を伴う眼疾患の処置剤 |
| US20240115545A1 (en) * | 2020-10-08 | 2024-04-11 | Curome Biosciences Co., Ltd. | Pharmaceutical composition containing b-lapachone as active ingredient for prevention or treatment of cholestatic liver disease |
| WO2024237730A1 (ko) * | 2023-05-18 | 2024-11-21 | 한국과학기술연구원 | 항-엔도글린 항체 및 이의 용도 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8529014D0 (en) | 1985-11-25 | 1986-01-02 | Biogen Nv | Enhanced secretion of heterologous proteins |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5462990A (en) | 1990-10-15 | 1995-10-31 | Board Of Regents, The University Of Texas System | Multifunctional organic polymers |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994010202A1 (en) | 1992-10-28 | 1994-05-11 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994010187A1 (en) | 1992-10-30 | 1994-05-11 | Hsc Research And Development Limited Partnership | COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-$g(b) |
| US5830847A (en) * | 1992-10-30 | 1998-11-03 | Hsc Research & Development Limited Partnership | Soluble TGF-β-binding endoglin polypeptides and homodimers |
| US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US6423501B2 (en) | 1996-12-13 | 2002-07-23 | Beth Israel Deaconess Medical Center | Calcium-independent negative regulation by CD81 of receptor signaling |
| MX9701946A (es) | 1997-03-14 | 1998-04-30 | Arturo Jimenez Bayardo | Solucion oftalmica transportadora. |
| ES2361267T3 (es) | 1997-04-07 | 2011-06-15 | Genentech Inc. | Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria. |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ES2273415T3 (es) | 1997-04-07 | 2007-05-01 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| AU7467898A (en) | 1997-04-21 | 1998-11-13 | Arch Development Corporation | Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy |
| DK1068241T3 (da) | 1998-04-02 | 2008-02-04 | Genentech Inc | Antistofvarianter og fragmenter deraf |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| HRP20030041A2 (en) | 2000-06-23 | 2005-02-28 | Schering Aktiengesellschaft | Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor fuction and their use (ii) |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| PL1638941T3 (pl) | 2003-05-22 | 2010-11-30 | Abbvie Bahamas Ltd | Indazolowe, benzizoksazolowe i benzizotiazolowe inhibitory kinaz |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20090170767A1 (en) | 2006-05-31 | 2009-07-02 | Beth Israel Deaconess Medical Center | Soluble Endoglin Compounds for the Treatment and Prevention of Cancer |
| US20090286271A1 (en) | 2006-05-31 | 2009-11-19 | Karumanchi Ananth S | Methods of Diagnosing and Treating Complications of Pregnancy |
| KR20170012582A (ko) | 2006-11-02 | 2017-02-02 | 악셀레론 파마 인코포레이티드 | Ａｌｋ１ 수용체 및 리간드 길항제 및 그의 용도 |
| CA2685306A1 (en) | 2007-06-01 | 2008-12-11 | Wyeth | Methods and compositions for modulating bmp-10 activity |
| EP2209003A1 (en) * | 2009-01-16 | 2010-07-21 | F. Hoffmann-Roche AG | Means and methods for differentiating between fibrosis and cirrhosis |
| US20100210713A1 (en) * | 2009-01-16 | 2010-08-19 | The General Hospital Corporation | Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor |
| ES2575695T3 (es) * | 2009-03-30 | 2016-06-30 | Acceleron Pharma Inc. | Antagonistas de BMP-ALK3 y sus usos para estimular el crecimiento óseo |
| ES2656232T3 (es) * | 2009-05-08 | 2018-02-26 | Novartis Ag | Métodos de modulación de fibrosis usando moduladores de la proteína morfogenética ósea 9 (BMP-9) |
| WO2011088047A1 (en) | 2010-01-12 | 2011-07-21 | Beth Israel Deaconess Medical Center | Soluble endoglin and uses thereof |
| AU2012245439B2 (en) | 2011-04-20 | 2017-04-06 | Acceleron Pharma, Inc. | Endoglin polypeptides and uses thereof |
| WO2013019805A1 (en) * | 2011-08-01 | 2013-02-07 | Tufts Medical Center, Inc. | Treatment of heart failure and related conditions |
| CA2962277C (en) * | 2013-09-20 | 2021-12-07 | Tufts Medical Center, Inc. | Methods and compositions for reducing cardiac damage and other conditions |
| EA035481B1 (ru) | 2013-10-25 | 2020-06-23 | Акселерон Фарма, Инк. | Эндоглиновые пептиды для лечения фиброзных заболеваний |
| US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
-
2014
- 2014-10-24 EA EA201690855A patent/EA035481B1/ru not_active IP Right Cessation
- 2014-10-24 AU AU2014339898A patent/AU2014339898B2/en not_active Ceased
- 2014-10-24 KR KR1020167013678A patent/KR102354787B1/ko not_active Expired - Fee Related
- 2014-10-24 CA CA2928708A patent/CA2928708A1/en not_active Abandoned
- 2014-10-24 EP EP14796626.1A patent/EP3060235B1/en active Active
- 2014-10-24 CN CN201480070781.XA patent/CN105899225A/zh active Pending
- 2014-10-24 WO PCT/US2014/062147 patent/WO2015061666A1/en not_active Ceased
- 2014-10-24 KR KR1020227001830A patent/KR20220013459A/ko not_active Ceased
- 2014-10-24 EA EA202090707A patent/EA202090707A1/ru unknown
- 2014-10-24 US US14/522,891 patent/US20150202260A1/en not_active Abandoned
- 2014-10-24 EP EP20201627.5A patent/EP3851118A1/en not_active Withdrawn
- 2014-10-24 JP JP2016526141A patent/JP6546587B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-21 JP JP2019115063A patent/JP6994481B2/ja not_active Expired - Fee Related
- 2019-09-05 US US16/561,991 patent/US11590201B2/en active Active
-
2020
- 2020-09-30 AU AU2020244463A patent/AU2020244463A1/en not_active Abandoned
-
2021
- 2021-12-13 JP JP2021201819A patent/JP2022058352A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535741A5 (enExample) | ||
| JP2016052315A5 (enExample) | ||
| JP2016000731A5 (enExample) | ||
| JP2010534486A5 (enExample) | ||
| JP2013534812A5 (enExample) | ||
| JP2016512213A5 (enExample) | ||
| JP2012509900A5 (enExample) | ||
| JP2015509707A5 (enExample) | ||
| RU2017134456A (ru) | Рекомбинантные связывающие белки и их применение | |
| JP2015212284A5 (enExample) | ||
| JP2009529509A5 (enExample) | ||
| JP2016187361A5 (enExample) | ||
| JP2019531055A5 (enExample) | ||
| JP2019033743A5 (enExample) | ||
| JP2018070625A5 (enExample) | ||
| JP2010539921A5 (enExample) | ||
| JP2018522563A5 (enExample) | ||
| FI2970398T3 (fi) | Rsv f -prefuusioproteiineja ja niiden käyttö | |
| JP2012082206A5 (enExample) | ||
| JP2019501647A5 (enExample) | ||
| JP2011501951A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| JP2021505156A5 (enExample) | ||
| JP2013027391A5 (enExample) | ||
| HRP20221531T1 (hr) | Pripravci faktora viii i postupci dobivanja i korištenja istih |